Is evening dosing of antihypertensive therapy ready for prime time?

Affiliations

Comment

John M Flack. J Clin Hypertens (Greenwich). 2014 Aug.

. 2014 Aug;16(8):557-8.

doi: 10.1111/jch.12355. Epub 2014 Jun 23.

No abstract available

Comment on

Evening dosing of antihypertensive therapy to reduce cardiovascular events: a third type of evidence based on a systematic review and meta-analysis of randomized trials.
Roush GC, Fapohunda J, Kostis JB. Roush GC, et al. J Clin Hypertens (Greenwich). 2014 Aug;16(8):561-8. doi: 10.1111/jch.12354. Epub 2014 Jul 16. J Clin Hypertens (Greenwich). 2014. PMID: 25039609 Free PMC article.

1. Hoshino A, Nakamura T, Matsubara H. The bedtime administration ameliorates blood pressure variability and reduces urinary albumin excretion in amlodipine‐olmesartan combination therapy. Clin Exp Hypertens. 2010;32:416–422. - PubMed
1. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiology Int. 2010;27:1629–1651. - PubMed
1. Roush GC, Fapohunda J, Kostis JB. Evening dosing of antihypertensives to reduce cardiovascular events: a third type of evidence based on a systematic review and meta‐analysis of randomized trials. J Clin Hypertens (Greenwich). 2014;16:561–568. - PMC - PubMed
1. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–153. - PubMed
1. Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause‐specific cardiovascular events in hypertension. Hypertension. 2008;51:55–61. - PubMed